About Combinati
Combinati is a company based in Palo Alto (United States) founded in 2015 by Megan Dueck, Andrew Zayac, and Paul Hung was acquired by Thermo Fisher Scientific in October 2021.. Combinati has raised $5.83 million across 1 funding round from investors including Thermo Fisher Scientific. Combinati offers products and services including QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix. Combinati operates in a competitive market with competitors including NeuMoDx, GenMark Diagnostics, Stilla Technologies, Biomeme and InDex Pharmaceuticals, among others.
- Headquarter Palo Alto, United States
- Founders Megan Dueck, Andrew Zayac, Paul Hung
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Thermo Fisher Scientific Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.83 M (USD)
in 1 rounds
-
Latest Funding Round
$5.83 M (USD), Series A
May 02, 2018
- Investors
-
Employee Count
Employee Count
-
Acquired by
Thermo Fisher Scientific
(Oct 04, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Combinati
Combinati offers a comprehensive portfolio of products and services, including QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
System for precise digital PCR quantification in research applications.
Probe-based kits for detecting and quantifying nucleic acids accurately.
Master mix for various digital PCR applications in gene editing.
Unlock access to complete
Unlock access to complete
Software Development Team
330 people
Leadership Team
169 people
Sales and Marketing
138 people
Human Resources and Administration
102 people
Product Management Team
68 people
Finance and Accounting
67 people
Senior Team
59 people
Operations Team
52 people
Unlock access to complete
Funding Insights of Combinati
Combinati has successfully raised a total of $5.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.83 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $5.8M
-
First Round
First Round
(02 May 2018)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Series A - Combinati | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Combinati
Combinati has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Electron microscopy services and microanalysis instruments are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Combinati
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Combinati
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Combinati Comparisons
Competitors of Combinati
Combinati operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuMoDx, GenMark Diagnostics, Stilla Technologies, Biomeme and InDex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of a platform for low cost molecular testing
|
|
| domain | founded_year | HQ Location |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| domain | founded_year | HQ Location |
Digital PCR solutions for research are developed and analyzed.
|
|
| domain | founded_year | HQ Location |
Smartphone-based DNA detection platform is developed for diagnostics.
|
|
| domain | founded_year | HQ Location |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| domain | founded_year | HQ Location |
Lab-on-a-chip technologies for miniaturized cell-biology testing are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Combinati
When was Combinati founded?
Combinati was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Where is Combinati located?
Combinati is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Who is the current CEO of Combinati?
Paul Hung is the current CEO of Combinati. They have also founded this company.
Is Combinati a funded company?
Combinati is a funded company, having raised a total of $5.83M across 1 funding round to date. The company's 1st funding round was a Series A of $5.83M, raised on May 02, 2018.
What does Combinati do?
Combinati is developing an integrated digital PCR platform with injection-molded microfluidic consumables to advance biomedical research. It uses consumable technology that allows high-density reagent digitization on a standard format using a scalable manufacturing process. The industry-standard format allows the integration of pneumatics thermal optical and software modules into one benchtop instrument to offer a significant workflow advantage over current commercially available products. Its precision nucleic acid quantification platform would accelerate the adoption of dPCR technology in the clinic for disease prevention prognosis diagnosis as well as therapeutics efficacy monitoring.
Who are the top competitors of Combinati?
Combinati's top competitors include GenMark Diagnostics, Stilla Technologies and NeuMoDx.
What products or services does Combinati offer?
Combinati offers QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix.
Who are Combinati's investors?
Combinati has 1 investor. Key investors include Thermo Fisher Scientific.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.